Reviva Pharmaceuticals Q2 EPS $(0.19) Beats $(0.39) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.39) by 50 percent. This is a 92.08 percent increase over losses of $(2.40) per share
Reviva lost less money than people expected—a good sign the company is improving. When a company loses less money over time, it means their business is getting stronger and moving toward profitability.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.